Tags: hepatitis C | infection | effective | Sovaldi | velpatasvir

New Combo Drug Effective Against All Hepatitis C

Image: New Combo Drug Effective Against All Hepatitis C
(Copyright AP)

Monday, 21 Sep 2015 12:12 PM


Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies.

The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's hep C drug, Sovaldi, with velpatasvir, an experimental NS5A inhibitor.

The main goal of each study was to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.

The combination is Gilead's second single-tablet treatment for hep C. Harvoni, its other treatment, is already approved for genotype 1 infections.

Sovaldi and Harvoni brought in combined sales of about $4.9 billion last quarter.

The U.S. Food and Drug Administration has granted the experimental combination "breakthrough therapy" status, expediting the development and review of the drug.

Gilead expects to file marketing applications for the combination - which could eliminate the need for HCV genotype testing altogether - by the fourth quarter, it said on Monday.

© 2017 NewsmaxHealth. All rights reserved.

   
1Like our page
2Share
Health-News
Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies. The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's hep C drug, Sovaldi, with...
hepatitis C, infection, effective, Sovaldi, velpatasvir
151
2015-12-21
Monday, 21 Sep 2015 12:12 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved